SCM
RETA
Silvant Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-3,483
| Closed | -$350K | – | 338 |
|
|
2021
Q3 | $350K | Hold |
3,483
| – | – | 0.06% | 141 |
|
|
2021
Q2 | $493K | Hold |
3,483
| – | – | 0.08% | 129 |
|
|
2021
Q1 | $347K | Hold |
3,483
| – | – | 0.06% | 150 |
|
|
2020
Q4 | $431K | Hold |
3,483
| – | – | 0.07% | 136 |
|
|
2020
Q3 | $339K | Hold |
3,483
| – | – | 0.06% | 137 |
|
|
2020
Q2 | $543K | Hold |
3,483
| – | – | 0.1% | 108 |
|
|
2020
Q1 | $503K | Hold |
3,483
| – | – | 0.11% | 102 |
|
|
2019
Q4 | $712K | Hold |
3,483
| – | – | 0.13% | 100 |
|
|
2019
Q3 | $280K | Buy |
3,483
+980
| +39% | +$78.8K | 0.06% | 147 |
|
|
2019
Q2 | $236K | Hold |
2,503
| – | – | 0.04% | 173 |
|
|
2019
Q1 | $214K | Hold |
2,503
| – | – | 0.04% | 184 |
|
|
2018
Q4 | $140K | Buy |
+2,503
| New | +$140K | 0.03% | 200 |
|